Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00.

In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 on February 9, maintaining a bullish outlook with a Buy rating. The firm updated its model on the company after its earnings, and told investors that it sees key upcoming catalysts for the company, including the fianlimab/Libtayo LAG-3 data in melanoma, an FDA decision for the Eylea HD pre-filled syringe in Q2, and an NDA submission for cemdisiran in generalized myasthenia gravis in Q1.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) also received a rating update from Oppenheimer on February 2, which lifted the price target on the stock to $865 from $750 while keeping an Outperform rating on the shares. It noted that Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) reported fiscal Q4 earnings were largely in-line with consensus estimates, and stated that the fiscal Q4 call sounded refreshingly optimistic after four consecutive quarters of EYLEA’s troubles dominating the discussion.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.